Uniqure N.V. (QURE) Stock Price, Quote & News

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 20 240 6000

Website: www.uniqure.com

Address:

Paasheuvelweg 25, Amsterdam, Netherlands

cubie Sep. 22 at 8:11 PM

$QURE congrats giddy bulls

0 · Reply

pnchv59 Sep. 22 at 7:42 PM

$QURE volume spike

0 · Reply

Thinkingman91 Sep. 22 at 7:01 PM

$CLPT $QURE I know nuffin

1 · Reply

Blockishot Sep. 22 at 2:24 PM

$QURE @daticecold Do you have a commercial supplier for Kool aid? I only ask because it appears you cant stop drinking it!

0 · Reply

daticecold Sep. 22 at 2:04 PM

$QURE If I am running a business, and I have 37 open job listings for this business, one would conclude that I have a product ready to sell, right? Now replace "Business" with "UniQure" and replace $40 a share with $140 a share. Simple stuff here folks!

1 · Reply

MABA1 Sep. 22 at 1:55 PM

$QURE Take a longboat with 20 of your finest men, head to where the sun sets, there you will find Uniqure's 4 year data: pillage, thunder, and burn all that you find!

1 · Reply

uranumo Sep. 21 at 2:05 PM

$QURE any reason to think that Heidi Overton‘s FDA run might have a direct effect on QURE?

0 · Reply

daticecold Sep. 19 at 3:43 PM

$QURE I hope you all are enjoying your weekend. As for me, I cannot wait for the weekend to be over! This is because next week UniQure will release the "Game Changer" for Huntington's Disease. Many thousands of dollars are on the line! How exciting.

1 · Reply

LotOfAction Sep. 18 at 7:43 PM

$QURE Added

0 · Reply

iQuicky Sep. 18 at 2:40 PM

$QURE too hot to ignore

0 · Reply

uniQure seeks US approval for Huntington's gene therapy after FDA reversal

2026-09-02T11:45:57.000Z - 20 days ago

uniQure submits biologics license application to FDA for ifezuntirgene inilparvo

Sep 2, 2026, 7:05 AM EDT - 20 days ago

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease

2026-09-02T10:45:21.000Z - 20 days ago

uniQure resumed with an Outperform at William Blair

2026-07-30T09:30:50.000Z - 7 weeks ago

uniQure price target lowered to $60 from $65 at Barclays

2026-07-29T20:16:22.000Z - 7 weeks ago

Wolfe upgrades uniQure to Outperform, sees ‘clear path to approval’ for AMT-130

2026-07-29T20:12:08.000Z - 7 weeks ago

uniQure upgraded to Outperform from Peer Perform at Wolfe Research

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

uniQure Earnings Call Transcript: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

uniQure Earnings release: Q2 2026

Jul 29, 2026, 8:30 AM EDT - 7 weeks ago

uniQure Quarterly report: Q2 2026

2026-07-29T11:30:54.000Z - 7 weeks ago

uniQure reports Q2 EPS ($1.22), consensus (71c)

Jul 29, 2026, 7:05 AM EDT - 7 weeks ago

uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

Jul 22, 2026, 7:05 AM EDT - 2 months ago

uniQure to Announce Second Quarter 2026 Financial Results

2026-06-29T10:00:16.000Z - 2 months ago

uniQure price target raised to $80 from $50 at H.C. Wainwright

Jun 25, 2026, 4:10 PM EDT - 2 months ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

2026-06-25T11:26:12.000Z - 2 months ago

uniQure price target raised to $68 from $35 at Mizuho

2026-06-24T01:51:45.000Z - 3 months ago

uniQure 4.95M share Spot Secondary priced at $45.50

Jun 23, 2026, 9:13 PM EDT - 3 months ago

uniQure Announces Pricing of Upsized $225 Million Public Offering

2026-06-23T18:40:00.000Z - 3 months ago

UniQure Stock (QURE) Gains on Public Offering Plans

2026-06-23T15:04:50.000Z - 3 months ago

uniQure rises 7.6%

2026-06-22T20:13:29.000Z - 3 months ago

uniQure announces $150M offering of common stock

Jun 22, 2026, 4:01 PM EDT - 3 months ago

uniQure Announces $150 Million Proposed Public Offering

2026-06-19T11:25:07.000Z - 3 months ago

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

$uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy$

Jun 19, 2026, 7:05 AM EDT - 3 months ago

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

2026-06-18T12:22:32.000Z - 3 months ago

Barclays upgrades uniQure, calls BLA submission ‘major positive’

2026-06-18T11:31:03.000Z - 3 months ago

uniQure price target raised to $70 from $36 at Leerink

Jun 17, 2026, 12:12 PM EDT - 3 months ago

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

Jun 17, 2026, 11:32 AM EDT - 3 months ago

What made uniQure stock nearly double on Wednesday?

Jun 17, 2026, 10:10 AM EDT - 3 months ago

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

Jun 17, 2026, 7:13 AM EDT - 3 months ago

UniQure gets FDA green light to file for Huntington's gene therapy approval

Jun 17, 2026, 7:05 AM EDT - 3 months ago

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease

May 5, 2026, 8:30 AM EDT - 4 months ago

uniQure Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

uniQure Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 months ago

uniQure Quarterly report: Q1 2026

May 5, 2026, 7:05 AM EDT - 4 months ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

Apr 30, 2026, 7:05 AM EDT - 4 months ago

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Apr 28, 2026, 7:05 AM EDT - 4 months ago

uniQure to Announce First Quarter 2026 Financial Results

Apr 27, 2026, 8:00 AM EDT - 4 months ago

uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

uniQure Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 5 months ago

uniQure Proxy statement: Proxy filing

Mar 9, 2026, 9:18 AM EDT - 6 months ago

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Mar 5, 2026, 6:01 PM EST - 6 months ago

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

Mar 5, 2026, 2:42 PM EST - 6 months ago

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Mar 5, 2026, 1:11 PM EST - 6 months ago

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

Mar 4, 2026, 11:01 PM EST - 6 months ago

FDA official says UniQure fell short on Huntington's trial, defends new study request

Mar 2, 2026, 10:30 AM EST - 6 months ago

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 6 months ago

uniQure Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:00 AM EST - 6 months ago

uniQure Earnings release: Q4 2025

Mar 2, 2026, 8:00 AM EST - 6 months ago

uniQure Annual report: Q4 2025

Mar 2, 2026, 7:22 AM EST - 6 months ago

FDA tells UniQure study data insufficient for brain disorder therapy application

Mar 2, 2026, 7:05 AM EST - 6 months ago

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

Feb 25, 2026, 6:00 PM EST - 6 months ago

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

Feb 23, 2026, 7:05 AM EST - 7 months ago

uniQure to Announce 2025 Financial Results

Feb 18, 2026, 10:06 AM EST - 7 months ago

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 17, 2026, 8:16 AM EST - 7 months ago

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Feb 6, 2026, 7:05 AM EST - 7 months ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

cubie Sep. 22 at 8:11 PM

$QURE congrats giddy bulls

0 · Reply

pnchv59 Sep. 22 at 7:42 PM

$QURE volume spike

0 · Reply

Thinkingman91 Sep. 22 at 7:01 PM

$CLPT $QURE I know nuffin

1 · Reply

Blockishot Sep. 22 at 2:24 PM

$QURE @daticecold Do you have a commercial supplier for Kool aid? I only ask because it appears you cant stop drinking it!

0 · Reply

daticecold Sep. 22 at 2:04 PM

1 · Reply

MABA1 Sep. 22 at 1:55 PM

$QURE Take a longboat with 20 of your finest men, head to where the sun sets, there you will find Uniqure's 4 year data: pillage, thunder, and burn all that you find!

1 · Reply

uranumo Sep. 21 at 2:05 PM

$QURE any reason to think that Heidi Overton‘s FDA run might have a direct effect on QURE?

0 · Reply

daticecold Sep. 19 at 3:43 PM

1 · Reply

LotOfAction Sep. 18 at 7:43 PM

$QURE Added

0 · Reply

iQuicky Sep. 18 at 2:40 PM

$QURE too hot to ignore

0 · Reply

FNMA2026 Sep. 17 at 6:52 PM

$QURE Yup it’s coming in the blink of an eye

1 · Reply

FNMA2026 Sep. 17 at 6:26 PM

$QURE THE BIG KAHUNA.

0 · Reply

QuantInsider Sep. 17 at 5:36 PM

$QURE popping 3.2% today but still down 1.9% over five days Looks like a quick bounce on news, not a long-term move yet Watch if it can hold above resistance Options flow is light Spotted a 500-contract Oct 16 $70 call sweep on InsiderFinance Someone's betting on upside with AMT-130 catalysts but it's too small to be a big institutional signal With high IV at 118%, better to play it safe with call spreads or hedged positions Too much risk for naked plays given the upcoming FDA news

0 · Reply

Blockishot Sep. 17 at 3:51 PM

$QURE @daticecold is a bonafide moron. If this “4 year data” is poor, this ship is going keel up and to the bottom. Wouldn’t be surprised to see @daticecold in a Titan submersible searching the wreck for fools gold once it sinks.

2 · Reply

daticecold Sep. 17 at 3:27 PM

$QURE No one is factoring in the 4 year data into BLA approval into buyout. My shares are conservatively worth $500 a piece in that scenario. If you could buy something 90% off, would you?

1 · Reply

judgeyoung2 Sep. 17 at 10:07 AM

$QURE alright they have an hour

1 · Reply

MAGA1717 Sep. 16 at 7:39 PM

$QURE BO incoming

0 · Reply

CC_Abbott Sep. 16 at 11:19 AM

$REPL $QURE $RGNX For any interested, a WSJ article covering biotech https://www.wsj.com/health/pharma/trump-administration-shift-puts-this-corner-of-biotech-back-in-favor-2abc0ae3?st=MqN8Gs&reflink=desktopwebshare_permalink (gift link) Disclosure: long QURE, RGNX; NFA & GL

1 · Reply

judgeyoung2 Sep. 15 at 8:39 PM

$QURE $CGON $AVBP might be worth doing cheap lottos on these in case they drop data before 9/18 opex. Not sure if Uniqure will move much though.

0 · Reply

MABA1 Sep. 14 at 3:42 PM

$QURE Going up today, stop woth the ball tickling and release the press release with the data 😩

1 · Reply

Thinkingman91 Sep. 14 at 3:05 PM

$QURE 50-72 is what I told you. Data drop before end of September $CLPT lagging wayyyy behind but what do I know

1 · Reply

et1000 Sep. 11 at 11:14 PM

Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $FATN $NEON $LAC $QURE need news

0 · Reply

Market Cap	3.05B
Revenue (ttm)	16.10M
Net Income (ttm)	-198.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,235.84%
Debt to Equity Ratio	0.15

Volume	1,131,011
Avg Vol	1,264,284
Day's Range	N/A - N/A
Shares Out	69.37M
Stochastic %K	50%
Beta	0.94
Analysts	Strong Sell
Price Target	$67.45